<DOC>
	<DOCNO>NCT02059720</DOCNO>
	<brief_summary>A multicentre , prospective , open-label clinical study , include randomize control study low intermediate-risk group patient , cohort study maintenance treatment decitabine ASCT .</brief_summary>
	<brief_title>Haplo-SCT v ASCT With Without Decitabine AML CR1</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Age &gt; = 18y Diagnosed AML ( except acute promyelocytic leukemia M3 ) first time Minimal Residual Disease ( MRD ) test achieve ( molecular biology first applicatable , and/or cytogenetics and/or immunophenotyping ) Presence available haplomismatch relate donor Contraindications chemotherapy hematopoietic stem cell transplantation Presence available identical sibling donor 10/10 HLA locimatched unrelated donor Participating clinical trial concern prophylaxis disease recurrence ASCT No effective contraception Pregnant lactating females Other cause suitable trial investigator 's consideration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>autologous hematopoietic stem cell transplantation</keyword>
	<keyword>maintenance treatment</keyword>
	<keyword>hematopoietic stem cell transplantation</keyword>
</DOC>